ZenaTech, the largest shareholder of Boardwalktech Software Corp., has requisitioned a shareholder meeting to replace the current board with its nominees, citing the company's financial struggles, declining revenue, and poor governance. Boardwalktech has faced repeated financial covenant breaches, significant revenue decline, and ongoing losses, with auditors raising doubts about its ability to continue as a going concern. ZenaTech plans to inject capital, expand sales channels, and improve governance to revive the company and increase shareholder value. The move signals a potential major shift in Boardwalktech's management and strategy to stabilize and grow the business.
ZenaTech Inc.'s requisition of a shareholder meeting to change Boardwalktech Software Corp.'s board comes as context for readers following the technology sector. For readers following technology stocks, here is Pluang's market snapshot as of Oct 01, 2026 21:22 WIB: Of 150 priced technology-sector US stocks tradable on Pluang, 97 rose and 53 fell today. Notable movers include IT (Gartner Inc) at USD 198.64 with a 1-day change of +6.49% and a typical hold time of 64 days, CDNS (Cadence Design Systems Inc) at USD 350.39 with a 1-day change of +6.12% and Pluang order activity of 80% Sell / 20% Buy, and APPN (Appian Corp) at USD 37.39 with a 1-day change of +6.01% and a typical hold time of 21 days.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
